AstraZeneca: encouraging results for Tagrisso

(CercleFinance.com) - AstraZeneca today presented preliminary results from a phase II trial showing that Tagrisso (osimertinib), in combination with savolitinib, resulted in an objective response rate (ORR) of 49% in patients with certain EGFR-mutated non-small cell lung cancers (NSCLC).


The highest ORR was observed in patients with high MET levels who had not been treated with prior chemotherapy. In patients whose tumours did not have high MET levels, the ORR was 9%.

While the current standard of care for patients with EGFR-mutated lung cancer is chemotherapy, the results of this trial suggest that savolitinib plus Tagrisso at the time of disease progression may be a potentially less toxic and more effective treatment option.


Copyright (c) 2022 CercleFinance.com. All rights reserved.